While a patient is receiving antilipemic therapy, the nurse knows to monitor the patient closely for the development of which problem?

Choice A reason: Neutropenia is not a common side effect of antilipemic therapy, like statins, which primarily affect lipid metabolism and liver function. Other drugs, like chemotherapy, cause neutropenia. This is incorrect, as liver dysfunction is the primary concern to monitor in antilipemic therapy. Choice B reason: Antilipemic therapy, especially statins, can cause liver dysfunction due to hepatotoxicity, elevating liver enzymes. Regular monitoring of liver function tests is essential to detect damage early, making this the correct problem for the nurse to monitor closely in patients on these medications. Choice C reason: Vitamin C deficiency is unrelated to antilipemic therapy, which affects lipid and liver metabolism. Dietary deficiencies cause scurvy, not statins. This is incorrect, as liver dysfunction, not vitamin deficiency, is the primary concern requiring monitoring during antilipemic treatment. Choice D reason: Pulmonary problems are not a primary side effect of antilipemic therapy, which mainly risks liver and muscle toxicity. Respiratory issues may relate to other conditions, not statins, making this incorrect, as liver dysfunction is the key problem to monitor in these patients.